Department of Pharmaceutical Sciences, School of Pharmacy, Southwest Medical University, Luzhou, PR China.
Department of Pharmacy of Traditional Chinese Medicine, School of Pharmacy, Southwest Medical University, Luzhou, PR China.
Drug Deliv. 2023 Dec;30(1):2174206. doi: 10.1080/10717544.2023.2174206.
Resveratrol is a polyphenol with diverse pharmacological activities, but its clinical efficacy is limited due to low solubility/permeability, light-induced isomerization, auto-oxidation, and rapid metabolism. Nanodelivery systems, such as liposomes, polymeric nanoparticles, lipid nanocarriers, micelles, nanocrystals, inorganic nanoparticles, nanoemulsions, protein-based nanoparticles, exosomes, macrophages, and red blood cells (RBCs) have shown great potential for improving the solubility, biocompatibility, and therapeutic efficacy of resveratrol. This review comprehensively summarizes the recent advances in resveratrol nanoencapsulation and describes potential strategies to improve the pharmacokinetics of existing nanoformulations, enhance targeting, reduce toxicity, and increase drug release and encapsulation efficiency. The article also suggests that in order to avoid potential safety issues, resveratrol nanoformulations must be tested in a wide range of diseases.
白藜芦醇是一种具有多种药理活性的多酚,但由于其溶解度/渗透性低、光致异构化、自动氧化和快速代谢,其临床疗效受到限制。纳米递药系统,如脂质体、聚合物纳米粒、脂质纳米载体、胶束、纳米晶体、无机纳米粒子、纳米乳液、基于蛋白质的纳米粒子、外泌体、巨噬细胞和红细胞(RBC),已显示出在提高白藜芦醇的溶解度、生物相容性和治疗效果方面的巨大潜力。本综述全面总结了白藜芦醇纳米包封的最新进展,并描述了潜在的策略,以改善现有纳米制剂的药代动力学,增强靶向性,降低毒性,增加药物释放和包封效率。文章还建议,为了避免潜在的安全问题,必须在广泛的疾病中测试白藜芦醇纳米制剂。